| Literature DB >> 33167735 |
Hyun Cheol Chung1, Yung-Jue Bang2, Charles S Fuchs3, Shu-Kui Qin4, Taroh Satoh5, Kohei Shitara6, Josep Tabernero7, Eric van Cutsem8, Maria Alsina7, Zhu Alexander Cao9, Jia Lu9, Pooja Bhagia9, Chie-Schin Shih9, Yelena Y Janjigian10.
Abstract
Treatment options for patients with HER2-positive advanced gastric cancer are limited, and the prognosis for these patients is poor. Pembrolizumab has demonstrated promising antitumor activity in patients with advanced gastric or gastroesophageal junction adenocarcinoma as monotherapy, in combination with chemotherapy and in combination with trastuzumab. Combining pembrolizumab with trastuzumab and chemotherapy may therefore provide a benefit for patients with advanced HER2-positive gastric cancer. Here we aimed to describe the design of and rationale for the randomized, double-blind, placebo-controlled Phase III KEYNOTE-811 study, which will evaluate the efficacy and safety of pembrolizumab or placebo in combination with trastuzumab and chemotherapy as first-line treatment for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma. Clinical trial registration: NCT03615326 (ClinicalTrials.gov).Entities:
Keywords: chemotherapy; first-line therapy; gastric cancer; gastroesophageal junction cancer; human epidermal growth factor receptor 2; pembrolizumab; trastuzumab
Year: 2020 PMID： 33167735 DOI： 10.2217/fon-2020-0737
Source DB: PubMed Journal: Future Oncol ISSN： 1479-6694 Impact factor: 3.404